The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C - II | Alive

Total Raised


Last Raised

$28M | 2 yrs ago

About V-Wave

V-Wave has developed a miniature valve that is implanted by catheterization into the left ventricle. This reduces the pressure on the muscle by controlling the blood flow between the heart chambers in patients who are frequently hospitalized with heart attacks. The valve is intended to reduce hospitalizations and improve patients' quality of life.

V-Wave Headquarter Location

5 Tarshish Street

Caesarea Business Park, 3088900,


+972 77 316 8550

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing V-Wave

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned V-Wave in 1 CB Insights research brief, most recently on Mar 26, 2020.

Expert Collections containing V-Wave

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

V-Wave is included in 3 Expert Collections, including Medical Devices.


Medical Devices

9,303 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,900 items

V-Wave Patents

V-Wave has filed 57 patents.

The 3 most popular patent topics include:

  • Cardiology
  • Heart diseases
  • Cardiac anatomy
patents chart

Application Date

Grant Date


Related Topics




Cardiovascular physiology, Cardiology, Heart diseases, Cardiac arrhythmia, Cardiac anatomy


Application Date


Grant Date



Related Topics

Cardiovascular physiology, Cardiology, Heart diseases, Cardiac arrhythmia, Cardiac anatomy



Latest V-Wave News

09:00 EDT V-Wave's Ventura® Interatrial Shunt: One Year Follow-up from RELIEVE-HF Roll-in Arm Shows Improved Left and Right Vent...

May 23, 2022

News provided by Share this article Share this article Echo Core Laboratory Data Demonstrates the Potential of a 5-mm Diameter Shunt to Reduce Filling Volumes and Enhance Systolic Function of Both Ventricles, Consistent with Reverse Cardiac Remodeling MADRID, May 23, 2022 /PRNewswire/ -- V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy. The patients were enrolled in 57 hospitals from 8 countries. The findings were presented at the European Society of Cardiology Heart Failure meeting by Spanish structural heart disease expert, Professor Julio Nunez from the University of Valencia. Patients were implanted with the shunt during a minimally invasive procedure and were discharged home the next day. In this Roll-in cohort there were no procedure- or device-related major adverse cardiac or neurological events. After 12 months, patients with moderate or severely reduced left ventricular ejection fraction (LVEF) had significantly improved LVEF by 4.6±9.3 (p=0.008) absolute % as compared to baseline prior to shunt implantation. Likewise, measures of RV systolic function including right ventricular fractional area change (RVFAC) and tricuspid annular plane systolic excursion (TAPSE), improved by 5.5±9.1 absolute % and 1.5±2.5 mm, respectively, regardless of baseline LVEF (p<0.0001 for both). Several additional indices of LV and RV dimensions and systolic function similarly improved. As there were no substantive changes in medical therapy, the authors observed that the findings likely resulted from the shunt device unloading high diastolic pressures in the LV, while not volume overloading the right-side of the heart. "Even in our population of advanced Heart Failure patients, we saw improvement in multiple indices of cardiac function." Dr. Nunez explained, "We hypothesized that the V-Wave shunt with a 5-mm diameter orifice, would not cause right heart dilatation and deterioration from chronic volume overloading, which has been seen with the use of a larger (8-mm) shunt. To our delight, we found multiple indicators that the RV was actually getting better. This may be clinically important considering the recent negative REDUCE-LAP-HF II trial that used a different and larger 8-mm interatrial shunt that has about twice the flow as the 5-mm V-Wave Ventura Shunt. One reason for lack of efficacy seen in REDUCE LAP-HF II may have been that their shunt overloaded the RV with excessive blood volume. We have knowledge from decades of treating patients with congenital atrial shunts that if they are too big, they must be closed before they cause irreversible injury to the right-heart, whereas if they are smaller, they can be left untreated because they do not cause harm." "These findings establish a basis for the hypothesis that a correctly sized shunt may allow both ventricles to beneficially (reverse) remodel, thus restoring cardiac function for the longer term. Even in our population of advanced Heart Failure patients, we saw improvement in multiple indices of cardiac function," said Professor William Abraham, MD, V-Wave's Chief Medical Officer. "More importantly the randomization arm of the RELIEVE-HF clinical trial is now enrolling the same high-risk HF patient population in a double-blind randomized controlled trial. Enrollment is expected to be completed by the Fall of 2022. Primary results will be available when the last enrolled patient has been followed for 12 months. This should provide the most definitive answer to date on the safety and effectiveness of interatrial shunting for HF. "  HF is the end-stage of most forms of heart disease, affecting six million Americans and more than 60 million people worldwide. Despite advances in therapy, premature death, recurrent hospitalization, and deteriorating quality-of-life remain a growing problem and represent a large burden to healthcare systems. "These data further support our strategy that using appropriate clinical criteria for inclusion of patients at high risk for HF-related untoward events, in conjunction with an optimally sized interatrial shunt may be safe and result in improved cardiac function,"  said Dr. Neal Eigler, MD, and CEO of V-Wave. "Moreover, this strategy does not to require the additional complexity and cost of performing invasive hemodynamic exercise testing to determine candidacy for shunt placement. This is an exciting time in cardiology, where the nexus of newer pharmaceuticals and compatible device therapies has the potential to create synergistic improvements that could benefit a very large number of patients suffering from advanced HF." About RELIEVE-HF About V-Wave Ltd. V-Wave is a privately held medical device company with offices in Israel and the U.S. For more information, please visit www. . This press release contains certain forward-looking statements that involve risks and uncertainties, including statements related to clinical development and potential regulatory approval of V-Wave's products. All forward-looking statements and other information included in this press release are based on information available to V-Wave as of the date hereof, and the Company assumes no obligation to update any such forward-looking statements or information. The company's actual results could differ materially from those described in the company's forward-looking statements. CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use. The V-Wave Ventura® Interatrial Shunt System is not available for sale in the United States or other countries. Contact

V-Wave Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

V-Wave Rank

  • When was V-Wave founded?

    V-Wave was founded in 2010.

  • Where is V-Wave's headquarters?

    V-Wave's headquarters is located at 5 Tarshish Street, Caesarea Business Park.

  • What is V-Wave's latest funding round?

    V-Wave's latest funding round is Series C - II.

  • How much did V-Wave raise?

    V-Wave raised a total of $128M.

  • Who are the investors of V-Wave?

    Investors of V-Wave include Pontifax, BRM Group, Edwards Lifesciences, Pura Vida Investments, TriVentures and 9 more.

  • Who are V-Wave's competitors?

    Competitors of V-Wave include Biofourmis, EarLens, Cardiac Insight, Eko, VitalConnect, Hillrom Holdings, Babyscripts, Implandata Ophthalmic Products, Intelligent Implants, Microtech Medical and 30 more.

You May Also Like

AliveCor Logo

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG.

MC10 Logo

MC10 is developing electronic systems through its Conformal Electronics Platform. The platform enhances and enables applications by allowing electronics to occupy spaces and geometries not possible in traditional, rigid form. Backed by a patent portfolio secured both through in-licensing and continued developments at MC10, the company is targeting applications in consumer electronics, medical devices, industrial products, and defense systems.

Vectorious Medical Technologies Logo
Vectorious Medical Technologies

Vectorious Medical Technologies is developing a cardiac monitoring system for congestive heart failure patients. Vectorious technology helps physicians to help patients help themselves. Via a simple, minimally-invasive implanted device, easy-to-access data and user-friendly external home-unit; the Vectorious system increases CHF patient quality of life and reduces readmission rates.

CeQur Logo

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

Triple Jump

Triple Jump develops a small insulin pump patch that is placed on the patient’s body. The patch has mobile connectivity capabilities and will be included in a future artificial pancreas system.

Intuity Medical Logo
Intuity Medical

Intuity Medical seeks to simplify diabetes management for persons living with diabetes. The company is developing a blood glucose monitoring system designed to make testing easy, convenient and discreet.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.